Clinical Strategies for Alzheimer's Disease Diagnosis and Management
Summary
Alzheimer’s disease presents as a gradual decline in memory, cognition and functional independence, underpinned by characteristic amyloid and tau pathology. Clinical approaches span from primary-care screening to specialist evaluation, incorporating cognitive assessments, neuroimaging and fluid biomarkers to identify disease in preclinical and prodromal stages. Early and accurate diagnosis enables timely intervention, care planning and access to emerging disease-modifying therapies, while minimising the risk of misattribution to normal ageing. Management strategies employ a multidisciplinary framework that includes pharmacological symptom control, non-pharmacological interventions such as cognitive stimulation and lifestyle modification, and coordination of psychosocial support for patients and carers. As novel therapies emerge, health-system preparedness—covering workforce training, diagnostic infrastructure and equitable service delivery—becomes ever more critical to translate scientific advances into improved patient outcomes.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Clinical Strategies for Alzheimer's Disease Diagnosis and Management publication trend
The graph below shows the total number of articles in clinical strategies for alzheimer's disease diagnosis and management across all publications each year (not limited to Nature Index journals).
Technical terms
Mild cognitive impairment (MCI): A transitional clinical state characterised by measurable cognitive decline without significant impact on daily functioning.
Biomarker: A measurable indicator of biological processes, used in Alzheimer’s to detect amyloid, tau or neurodegeneration via imaging or fluid assays.
Disease-modifying therapy (DMT): A treatment intended to slow or halt the underlying pathological progression rather than simply alleviate symptoms.
Positron emission tomography (PET): A neuroimaging technique that uses radiotracers to visualise molecular pathology such as amyloid-β or tau deposition in the brain.
Cerebrospinal fluid (CSF): The clear fluid surrounding the brain and spinal cord, analysed to quantify levels of Alzheimer’s-related proteins.
References
- Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. The Journal of Prevention of Alzheimer's Disease (2021).
- Understanding the role of psychiatrists in the diagnosis and management of mild cognitive impairment and mild Alzheimer’s disease dementia: a cross-sectional survey. BMC Psychiatry (2023).
- Geographic variation in shortfalls of dementia specialists in the United States. Health Affairs Scholar (2024).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.